MedTrace Logo

Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer

NCT00471276 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2011-07-25

Study results available
· View outcomes & findings →

Summary

Patients with advanced breast cancer to receive sunitinib (Sutent) once daily until disease progression.

Conditions

  • Breast Neoplasms

Interventions

DRUG

sunitinib

sunitinib (Sutent), 37.5 mg, daily dosing

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00471276 on ClinicalTrials.gov